Why Citius Pharmaceuticals Stock Is Plunging Today?
Portfolio Pulse from Vandana Singh
The FDA has issued a Complete Response Letter to Citius Pharmaceuticals Inc's (NASDAQ:CTXR) Biologics License Application for denileukin diftitox (Lymphir), requiring enhanced product testing and additional controls. The FDA had no concerns about the safety and efficacy data submitted. In 2021, Citius acquired an exclusive license to develop and commercialize Lymphir in all markets except Japan and certain parts of Asia. CTXR shares are down 16% at $0.94.
July 31, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citius Pharmaceuticals' stock is down 16% following the FDA's requirement for enhanced product testing and additional controls for their denileukin diftitox.
The FDA's requirement for enhanced product testing and additional controls for Citius Pharmaceuticals' denileukin diftitox has negatively impacted investor sentiment, leading to a 16% drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100